IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
A more comprehensive dataset on JANX007 sends the group’s stock down.
But the group still hopes to get IGV-001 approved based on overall survival data.
The agency approved eight oncology products over the month.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
The pivotal Harmoni-GI3 study has started enrolling patients.
Varegacestat’s pivotal study reads out imminently.
